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Implication for health policy/practice/research/medical education:
In a double blind clinical trial on 32 hemodialysis patients who suffered from intradialytic hypotension, in more than 50% of 
dialysis sessions, we found that the administration of sertraline or L-carnitine for one month could significantly increase the 
mean systolic blood pressure, mean diastolic blood pressure, and mean arterial pressure and also nadir blood pressures while 
there was no significant difference between both drugs.
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Although dialysis is an effective method for the management 
of end-stage kidney disease (ESKD), it is associated with 
some complications, including intradialytic hypotension 
(IDH). There is no consensus regarding the definition 
of IDH, but the Disease Outcomes Quality Initiative 
(KDOQI) defines this condition as a decrease of 20 mm 
Hg or more in systolic blood pressure (SBP) or a decrease 
of 10 mm Hg or more in mean arterial pressure (MAP) 
requiring therapeutic interventions (1). The incidence of 
symptomatic hypotension during or immediately after 
dialysis is reported in 5%–30% of all dialysis sessions (2,3). 
Moreover, some patients experience IDH in more than 
50% of their dialysis sessions (4).
Introduction: Although some studies have reported the positive effect of sertraline and 
L-carnitine on intradialytic hypotension (IDH), a common complication of dialysis, however 
the results are controversial.
Objectives: The aim of this study was to compare the effects of sertraline and L-carnitine on 
blood pressure in patients with chronic renal failure who were undergoing dialysis.
Patients and Methods: This double-blind clinical trial was conducted on 32 hemodialysis 
patients who suffered from IDH in more than 50% of dialysis sessions. Patients were randomly 
divided into two groups of sertraline (50 mg daily) and L-carnitine (1000 mg daily), with 16 
patients in each group. Duration of treatment was four weeks, then patients were followed up for 
additional three weeks. The changes in patients’ blood pressure were monitored in each group 
and the results compared between the two groups.
Results: Of all, 18 patients (56%) were female, 14 patients (44%) were male, and their mean 
(SD) age was 60 ± 15 years. At the end of the study, mean systolic blood pressure (SBP), mean 
diastolic blood pressure (DBP), and mean arterial pressure (MAP) were significantly increased 
in both the sertraline and L-carnitine groups (P < 0.05). In addition, nadir SBP, nadir DBP, 
and nadir MAP in each group were significantly increased compared to pre-treatment period 
(P < 0.001). An increase of more than 5 mm Hg in SBP, DPB, and MAP was observed in half of 
the subjects in the sertraline group and more than two-thirds of the patients in the L-carnitine 
group, however there was no significant difference between the two groups (P > 0.05).
Conclusion: The findings of this study showed that the administration of sertraline or L-carnitine 
for one month could significantly increase SBP, DBP, MAP, and nadir blood pressures in dialysis 
patients suffering from IDH during dialysis sessions because there was no significant difference 
between the two drugs.
Trial Registration: The trial protocol has been registered by the Iranian registry of clinical trial 
(IRCT20190624043997N1; https://irct.ir/trial/40941, ethical code # IR.QUMS.REC.1397.128). 









Received: 10 January 2020 
Accepted: 4 March 2020 




A B S T R A C T
